BIO CEO: Overcoming the Obstacles in Developing Gene Therapies
In the last decade, there have been over 5000 clinical trials and yet only 2 approved drugs in the gene therapy space. This underlines the challenges in pre-clinical development, clinical trials, regulatory approvals and commercialization. Each vertical has witnessed tremendous improvements to encourage biopharma to invest heavily in gene therapies to address unmet clinical needs.
In a panel discussion at the BIO CEO & Investor Conference, industry experts reflected on their experiences of navigating the commercialization and approval landscape for cell and gene therapies. Moderated by Luca Issi, Senior Biotech Research Analyst at RNC Capital Market, the session included
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02